Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression

NCT01078298 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01078298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01078298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
June 30, 2012
Enrollment
525 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

depression, smoking cessation